{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetComparison",
 "url": "https://clearank.com/compare/pfe-vs-mrk/",
 "dataUrl": "https://clearank.com/compare/pfe-vs-mrk/data.json",
 "title": "PFE vs MRK: Which Is the Better Buy? (2026)",
 "description": "PFE or MRK? Compare PFE vs MRK, daily AI-powered analysis with technical indicators, price targets, valuation, and a head-to-head verdict.",
 "headline": "Pfizer vs Merck & Co.",
 "published": "2026-06-07T09:17:25+00:00",
 "modified": "2026-09-26T18:51:05.444+00:00",
 "generated": "2026-09-27T13:24:03.305Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "assets": [
  {
   "ticker": "PFE",
   "dataUrl": "https://clearank.com/stock/pfizer-pfe/data.json"
  },
  {
   "ticker": "MRK",
   "dataUrl": "https://clearank.com/stock/merck-mrk/data.json"
  }
 ],
 "sections": [
  {
   "id": "verdict",
   "title": "Comparative Analysis",
   "text": [
    "Merck (MRK) wins this head-to-head comparison against Pfizer (PFE), primarily driven by its superior profitability and stronger revenue growth. While both companies operate in the pharmaceutical sector, MRK demonstrates a stronger financial profile. Its higher return on equity and assets, coupled with better revenue growth, suggest a more efficient and expanding business. PFE, despite a higher dividend yield, lags behind MRK in key profitability and growth metrics. MRK's ability to consistently beat earnings estimates, even on a negative EPS basis, indicates operational resilience and market confidence. Technically, both stocks show mixed signals, but MRK's stronger fundamentals provide a more compelling case for investment at this juncture. The valuation gap, while present, is justified by MRK's superior performance.",
    "Merck's (MRK) superior profitability, evidenced by its significantly higher return on equity and assets, is the key differentiator against Pfizer (PFE). This enhanced capital efficiency, combined with stronger revenue growth and a more positive analyst sentiment, positions MRK as the more compelling investment despite its higher valuation. MRK's ability to consistently beat earnings expectations further solidifies its operational strength.",
    "Merck (MRK) is expected to continue its upward trajectory, driven by its strong profitability and ongoing revenue growth, with analysts projecting a median target of $152.50. Pfizer (PFE) faces a more uncertain outlook, with its current price near the median analyst target and mixed fundamental indicators suggesting slower appreciation. In a bullish scenario, MRK could see further upside if its pipeline delivers blockbusters, while PFE might benefit from a broader market rally or successful cost-containment measures. Conversely, a bearish scenario for MRK would involve pipeline setbacks or increased competition, while PFE could face pressure if its revenue growth falters or if broader market sentiment turns negative."
   ]
  },
  {
   "id": "price",
   "title": "Price Analysis Comparison"
  },
  {
   "id": "valuation",
   "title": "Valuation Metrics",
   "text": [
    "Merck (MRK) trades at a significantly higher P/E ratio of 119.02 compared to Pfizer (PFE) at 36.60, indicating a premium valuation for MRK. However, MRK's price is closer to its 52-week high ($148.78 vs $156.92 high) than PFE ($28.67 vs $29.21 high), suggesting stronger recent price momentum for MRK. PFE's 52-week range is narrower ($23.58 to $29.21) compared to MRK's ($77.58 to $156.92), implying greater historical volatility for MRK. Despite the higher P/E, MRK's market capitalization is substantially larger ($367B vs $163B), reflecting its greater scale and market presence."
   ],
   "tables": [
    {
     "caption": "Valuation Metrics: PFE vs MRK",
     "columns": [
      "Metric",
      "PFE",
      "MRK"
     ],
     "rows": [
      {
       "label": "P/E Ratio",
       "cells": [
        "36.60",
        "119.02"
       ]
      },
      {
       "label": "Market Cap",
       "cells": [
        "163.41B",
        "367.07B"
       ]
      },
      {
       "label": "Price/Sales",
       "cells": [
        "2.52",
        "5.51"
       ]
      },
      {
       "label": "Price/Book",
       "cells": [
        "1.89",
        "8.76"
       ]
      },
      {
       "label": "EV/EBITDA",
       "cells": [
        "8.38",
        "14.34"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "6.00%",
        "2.29%"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "profitability",
   "title": "Profitability & Efficiency",
   "text": [
    "MRK also demonstrates significantly better capital efficiency with a return on assets of 11.87%, substantially higher than PFE's 5.78%. While PFE has a slightly higher net profit margin at 6.8%, MRK's stronger returns on equity and assets suggest more effective utilization of its capital base to generate profits."
   ],
   "tables": [
    {
     "caption": "Profitability & Efficiency: PFE vs MRK",
     "columns": [
      "Metric",
      "PFE",
      "MRK"
     ],
     "rows": [
      {
       "label": "Rev. Growth (Qtly)",
       "cells": [
        "2.60%",
        "5.10%"
       ]
      },
      {
       "label": "Profit Margin",
       "cells": [
        "6.80%",
        "4.77%"
       ]
      },
      {
       "label": "Return on Equity",
       "cells": [
        "5.01%",
        "6.96%"
       ]
      },
      {
       "label": "Return on Assets",
       "cells": [
        "5.78%",
        "11.87%"
       ]
      },
      {
       "label": "Debt/Equity",
       "cells": [
        "74.25",
        "128.41"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "earnings",
   "title": "Earnings Reality Check",
   "text": [
    "Earnings data unavailable. No recent report data found.",
    "Last 4 Qs: MRK beat estimates 4x out of 4. Rose 4x after beats."
   ]
  },
  {
   "id": "technicals",
   "title": "Technical Indicators",
   "text": [
    "Merck (MRK) is currently trading at $148.78, below its 20-day EMA ($146.96) but above its 50-day ($140.38) and 200-day ($121.67) SMAs, indicating a mixed but generally positive trend. Pfizer (PFE) is trading at $28.67, above its 20-day EMA ($27.91), 50-day ($26.98), and 200-day ($26.34) SMAs, suggesting a more consistent uptrend. MRK's RSI is 46.08, indicating neutral momentum, while PFE's RSI is 54.7, suggesting slightly more positive momentum. MRK's MACD of 1.90 is positive and above its signal line, indicating bullish momentum, whereas PFE's MACD of 0.28 is also positive but less pronounced."
   ],
   "tables": [
    {
     "caption": "Technical indicators: PFE vs MRK",
     "columns": [
      "Indicator",
      "PFE",
      "MRK"
     ],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "54.70",
        "46.08"
       ]
      },
      {
       "label": "50-Day MA",
       "cells": [
        "$26.98",
        "$140.38"
       ]
      },
      {
       "label": "200-Day MA",
       "cells": [
        "$26.34",
        "$121.67"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "sentiment",
   "title": "AI Analyst Sentiment",
   "text": [
    "Merck (MRK) garners a more favorable analyst rating consensus, with 5 'Strong Buy' and 15 'Buy' ratings out of 28 analysts, and a median target price of $152.50, suggesting potential upside from its current price. Pfizer (PFE) has a more mixed analyst outlook, with 2 'Strong Buy' and 8 'Buy' ratings, but also 16 'Hold' and 1 'Sell' rating among 28 analysts, and a median target price of $28.00, which is very close to its current trading price. The higher concentration of buy-side recommendations and a more optimistic price target for MRK suggest stronger positive sentiment from the analyst community."
   ]
  },
  {
   "id": "risk",
   "title": "Risk Stratification",
   "text": [
    "For Merck (MRK), the primary risks include its high P/E ratio, which could lead to significant downside if growth expectations are not met, and potential regulatory hurdles or clinical trial failures for its drug pipeline. Pfizer (PFE) faces risks related to its slower revenue growth and lower profitability metrics, which could hinder its ability to compete effectively in the long term. Its mixed analyst ratings also point to uncertainty about its future performance. Both companies are subject to broader pharmaceutical industry risks, including patent expirations, pricing pressures, and evolving healthcare policies. MRK's higher valuation makes it more susceptible to market sentiment shifts, while PFE's fundamental weaknesses present a more persistent operational challenge."
   ],
   "tables": [
    {
     "caption": "Risk metrics: PFE vs MRK",
     "columns": [
      "Metric",
      "PFE",
      "MRK"
     ],
     "rows": [
      {
       "label": "Beta (Volatility) i",
       "cells": [
        "0.30",
        "0.23"
       ]
      },
      {
       "label": "Sharpe Ratio",
       "cells": [
        "-0.14",
        "0.27"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "protips",
   "title": "Comparative ProTips",
   "lists": {
    "ProTips": [
     "Consider MRK for its stronger fundamental performance and growth potential, accepting the higher valuation.",
     "PFE's higher dividend yield may appeal to income-focused investors, but its fundamental metrics suggest caution.",
     "Monitor MRK's drug pipeline developments closely, as they are critical to sustaining its premium valuation."
    ]
   }
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)"
  },
  {
   "id": "trade-plans",
   "title": "Actionable Trade Plans",
   "text": [
    "Compare entry, exit, and risk management levels for both assets",
    "Volatility-Adjusted Stop Loss Calculated based on volatility and technical support levels."
   ],
   "facts": {
    "STOP LOSS": "$137.10"
   }
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "XRP/USD vs HBAR/USD XRP/USD vs HBAR/USD Comparison $1.55 -2.06%",
     "url": "https://clearank.com/compare/xrp-vs-hbar/"
    },
    {
     "text": "VGT vs SCHG VGT vs SCHG Comparison $126.17 +0.7828%",
     "url": "https://clearank.com/compare/vgt-vs-schg/"
    },
    {
     "text": "GD vs LMT General Dynamics (GD) vs Lockheed Martin (LMT) Comparison $336.72 +0.1279%",
     "url": "https://clearank.com/compare/general-dynamics-vs-lockheed-martin/"
    },
    {
     "text": "SOL/USD vs ADA/USD SOL/USD vs ADA/USD Comparison $120.56 +2.53%",
     "url": "https://clearank.com/compare/sol-vs-ada/"
    }
   ]
  }
 ],
 "faq": [
  {
   "question": "Which is a better buy, MRK or PFE?+",
   "answer": "Merck (MRK) is the preferred buy due to its superior profitability, stronger revenue growth, and more positive analyst sentiment, despite a higher valuation. Pfizer (PFE) lags in key financial metrics."
  },
  {
   "question": "What are the key risks for MRK vs PFE?+",
   "answer": "MRK faces risks from its high valuation and pipeline execution, while PFE's risks include slower growth and operational challenges. Both are exposed to industry-wide regulatory and pricing pressures."
  },
  {
   "question": "How do MRK and PFE compare on profitability?+",
   "answer": "Merck (MRK) is more profitable, showing a higher return on equity (6.96% vs 5.01%) and return on assets (11.87% vs 5.78%) compared to Pfizer (PFE)."
  },
  {
   "question": "What is the dividend yield for MRK and PFE?+",
   "answer": "Pfizer (PFE) offers a higher dividend yield of approximately 6.00%, while Merck (MRK) provides a yield of about 2.29%."
  },
  {
   "question": "How do their P/E ratios compare?+",
   "answer": "Pfizer (PFE) has a P/E ratio of 36.60, significantly lower than Merck's (MRK) P/E ratio of 119.02."
  },
  {
   "question": "What is the analyst sentiment for each stock?+",
   "answer": "Analysts favor Merck (MRK) more, with a higher proportion of 'Buy' ratings and a more optimistic median target price compared to Pfizer (PFE), which has a more mixed analyst outlook."
  },
  {
   "question": "How has their recent earnings performance been?+",
   "answer": "Merck (MRK) has consistently beaten earnings estimates, whereas Pfizer (PFE) has 'N/A' for recent earnings data, making direct comparison difficult."
  }
 ],
 "related": {
  "peopleAlsoWatch": [],
  "comparisons": [
   {
    "ticker": "XRP/USD vs HBAR/USD",
    "name": "XRP/USD vs HBAR/USD Comparison",
    "price": "$1.55",
    "change": "-2.06%",
    "url": "https://clearank.com/compare/xrp-vs-hbar/"
   },
   {
    "ticker": "VGT vs SCHG",
    "name": "VGT vs SCHG Comparison",
    "price": "$126.17",
    "change": "+0.7828%",
    "url": "https://clearank.com/compare/vgt-vs-schg/"
   },
   {
    "ticker": "GD vs LMT",
    "name": "General Dynamics (GD) vs Lockheed Martin (LMT) Comparison",
    "price": "$336.72",
    "change": "+0.1279%",
    "url": "https://clearank.com/compare/general-dynamics-vs-lockheed-martin/"
   },
   {
    "ticker": "SOL/USD vs ADA/USD",
    "name": "SOL/USD vs ADA/USD Comparison",
    "price": "$120.56",
    "change": "+2.53%",
    "url": "https://clearank.com/compare/sol-vs-ada/"
   }
  ],
  "Newly Tracked": [
   {
    "ticker": "KMB",
    "text": "Kimberly-Clark Corporation",
    "url": "https://clearank.com/stock/kmb-stock-analysis/"
   },
   {
    "ticker": "IAUM",
    "text": "iShares Gold Trust Micro",
    "url": "https://clearank.com/etf/iaum-etf-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "RENDER/USD",
    "text": "↑ 10.19%",
    "url": "https://clearank.com/crypto/render-render-usd/"
   },
   {
    "ticker": "ZS",
    "text": "↓ 10.06%",
    "url": "https://clearank.com/stock/zscaler-zs/"
   },
   {
    "ticker": "MXL",
    "text": "↑ 10.00%",
    "url": "https://clearank.com/stock/mxl-stock-analysis/"
   },
   {
    "ticker": "BE",
    "text": "↑ 8.27%",
    "url": "https://clearank.com/stock/be-stock-analysis/"
   },
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 8.20%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png",
     "width": "1200",
     "height": "630",
     "caption": "CleaRank head-to-head comparison",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/compare/pfe-vs-mrk/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/compare/pfe-vs-mrk/",
        "name": "PFE vs MRK Comparison"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/compare/pfe-vs-mrk/#webpage",
     "url": "https://clearank.com/compare/pfe-vs-mrk/",
     "name": "PFE vs MRK: Which Is the Better Buy? (2026)",
     "datePublished": "2026-06-07T09:17:25+00:00",
     "dateModified": "2026-09-26T18:51:05+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/compare/pfe-vs-mrk/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/compare/pfe-vs-mrk/#richSnippet",
     "headline": "PFE vs MRK: Which Is the Better Buy? (2026)",
     "name": "PFE vs MRK: Which Is the Better Buy? (2026)",
     "description": "PFE or MRK? Compare PFE vs MRK, daily AI-powered analysis with technical indicators, price targets, valuation, and a head-to-head verdict.",
     "datePublished": "2026-06-07T09:17:25+00:00",
     "dateModified": "2026-09-26T18:51:05+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "isPartOf": {
      "@id": "https://clearank.com/compare/pfe-vs-mrk/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/compare/pfe-vs-mrk/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "ItemList",
   "name": "PFE vs MRK Comparison",
   "url": "https://clearank.com/compare/pfe-vs-mrk/",
   "numberOfItems": 2,
   "itemListElement": [
    {
     "@type": "ListItem",
     "position": 1,
     "item": {
      "@type": "FinancialProduct",
      "name": "Pfizer Inc. (PFE)",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "PFE"
       }
      ],
      "description": "AI-driven analysis of Pfizer Inc. (PFE) - price targets, valuation, technicals.",
      "url": "https://clearank.com/stock/pfizer-pfe/"
     }
    },
    {
     "@type": "ListItem",
     "position": 2,
     "item": {
      "@type": "FinancialProduct",
      "name": "Merck & Co., Inc. (MRK)",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "MRK"
       }
      ],
      "description": "AI-driven analysis of Merck & Co., Inc. (MRK) - price targets, valuation, technicals.",
      "url": "https://clearank.com/stock/merck-mrk/"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Which is a better buy, MRK or PFE?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Merck (MRK) is the preferred buy due to its superior profitability, stronger revenue growth, and more positive analyst sentiment, despite a higher valuation. Pfizer (PFE) lags in key financial metrics."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks for MRK vs PFE?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "MRK faces risks from its high valuation and pipeline execution, while PFE's risks include slower growth and operational challenges. Both are exposed to industry-wide regulatory and pricing pressures."
     }
    },
    {
     "@type": "Question",
     "name": "How do MRK and PFE compare on profitability?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Merck (MRK) is more profitable, showing a higher return on equity (6.96% vs 5.01%) and return on assets (11.87% vs 5.78%) compared to Pfizer (PFE)."
     }
    },
    {
     "@type": "Question",
     "name": "What is the dividend yield for MRK and PFE?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Pfizer (PFE) offers a higher dividend yield of approximately 6.00%, while Merck (MRK) provides a yield of about 2.29%."
     }
    },
    {
     "@type": "Question",
     "name": "How do their P/E ratios compare?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Pfizer (PFE) has a P/E ratio of 36.60, significantly lower than Merck's (MRK) P/E ratio of 119.02."
     }
    },
    {
     "@type": "Question",
     "name": "What is the analyst sentiment for each stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Analysts favor Merck (MRK) more, with a higher proportion of 'Buy' ratings and a more optimistic median target price compared to Pfizer (PFE), which has a more mixed analyst outlook."
     }
    },
    {
     "@type": "Question",
     "name": "How has their recent earnings performance been?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Merck (MRK) has consistently beaten earnings estimates, whereas Pfizer (PFE) has 'N/A' for recent earnings data, making direct comparison difficult."
     }
    }
   ]
  }
 ]
}